PCOS Treatment Names: Drug Classes Used in India
The drug classes and molecules used to treat PCOS in India — letrozole, clomiphene, metformin, combined oral contraceptives — and where guidelines place each.
This PCOS names breakdown covers what each drug class does, where current guidelines place it in the treatment sequence, and why the sequence changed in 2023. It does not cover dosing; that decision sits with the treating gynaecologist or endocrinologist based on individual response and monitoring.
Why is letrozole now first-line instead of clomiphene?
Letrozole is recommended as first-line pharmacological therapy for ovulation induction in infertile, anovulatory PCOS with no other fertility factor, per the 2023 International Evidence-Based Guideline. This reversed decades of clomiphene citrate holding that position.
The guideline change rests on trial evidence showing letrozole produces higher ovulation and live-birth rates than clomiphene in this population. Clomiphene retains a role as a second-line agent, alone or combined with metformin, gonadotrophins or ovarian surgery, after benefits, risks and cost are explained to the patient.
Where does metformin fit in current PCOS guidelines?
Metformin's primary guideline-recommended role is metabolic: improving insulin resistance markers in women with PCOS, rather than acting as a first-choice ovulation agent. The 2023 guideline notes metformin has greater efficacy than inositol for this metabolic indication, which is a specific correction to inositol's marketed positioning as a metformin alternative.
Metformin can still be used alone to improve clinical pregnancy and live-birth rates in anovulatory infertility, but guidelines are explicit that more effective ovulation agents exist and patients should be informed of that before choosing metformin alone for fertility purposes specifically.
What is the guideline-recommended first-line treatment for irregular periods and hyperandrogenism?
Combined oral contraceptive pills are the first-line pharmacological treatment for menstrual irregularity and the hyperandrogenism symptoms of PCOS, namely acne and hirsutism, under the 2023 international guideline. No single preparation is specified as superior.
The guideline expresses a preference for lower ethinyl estradiol dose formulations with a more favourable side-effect profile, without naming one brand or formulation as mandatory. This is a class-level recommendation, and the specific formulation is a prescriber decision based on the individual patient's risk profile.
When is an anti-androgen like spironolactone added to treatment?
Anti-androgens, spironolactone being the most commonly used, are typically added when combined oral contraceptives alone don't adequately control hirsutism or acne, or when contraceptives are contraindicated. This positions anti-androgen therapy as an adjunct rather than a first-line monotherapy in most guideline pathways.
Spironolactone carries a specific reproductive safety consideration: it is not used without reliable contraception in place, given teratogenicity concerns, which is one reason it is typically paired with a combined oral contraceptive rather than used alone in a woman not actively avoiding pregnancy.
Does inositol have a guideline-supported role in PCOS?
Inositol's role is more limited than its consumer marketing suggests. A systematic review and meta-analysis conducted specifically to inform the 2023 guideline update found inositol offers limited clinical benefit compared to metformin for the metabolic features of PCOS.
This matters clinically because inositol supplements are widely sold and marketed directly to patients as a PCOS treatment, often without the guideline caveat that metformin is the better-evidenced option for the same metabolic indication. A prescriber weighing the two is working from a meta-analysis specifically built to settle this comparison, not from marketing claims either product makes.
How does this drug-class mix affect what a hospital pharmacy needs to stock?
A gynaecology or endocrinology OPD treating PCOS routinely writes across all four drug classes in the same clinic day: an ovulation-induction agent for one patient, metformin for another, a contraceptive pill for a third, and an anti-androgen for a fourth. That is a wider stocking requirement than a single-drug specialty clinic, and a gap in any one class sends that specific prescription to an outside chemist.
Because PCOS is a chronic, recurring-visit condition rather than a one-time prescription, a hospital that reliably stocks this full class mix in-house keeps the patient's refill cycle, and the revenue on it, inside the hospital across years of follow-up rather than losing it after the first visit. Medyzen's managed hospital pharmacy services piece covers how that stocking model is built, and the prescription leakage piece covers what a hospital loses on chronic-condition patients specifically when refills routinely walk out the door. Our PCOS treatment guide covers the broader diagnostic and lifestyle picture beyond the drug classes here.
Working through these PCOS names by class, rather than by brand, is also the only way to compare them fairly: two brands built on the same molecule behave identically, while two different molecules in the same class can carry meaningfully different guideline weight, as letrozole and clomiphene show.
Sources
- 1Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — Journal of Clinical Endocrinology & Metabolism, National Institutes of Health, PMC
- 2International Evidence-based Guideline for the Assessment and Management of PCOS 2023 — full guideline — Monash University, coordinating centre for the guideline
- 3Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update — National Institutes of Health, PMC
- 4Summary of the 2023 international evidence-based guideline for PCOS: an Australian perspective — Medical Journal of Australia
- 5Recommendations from the 2023 International Evidence-based Guideline — American Society for Reproductive Medicine, practice guidance
This article is for informational purposes and is not a substitute for professional medical advice. It describes drug classes and guideline positioning, not dosing or individual prescribing decisions. Consult a treating gynaecologist or endocrinologist for individual case management.
FAQ
Frequently asked questions
Letrozole, per the 2023 International Evidence-Based Guideline for PCOS, which found it produces higher ovulation and live-birth rates than clomiphene citrate in anovulatory infertility with no other fertility factor present.
Metformin's primary guideline role is improving insulin resistance and metabolic markers. It can support ovulation and pregnancy rates used alone, but guidelines note more effective ovulation-specific agents exist.
Both induce ovulation, but current guidelines place letrozole first-line based on higher ovulation and live-birth rates in trials, with clomiphene retained as a second-line option, often combined with metformin.
Combined oral contraceptives are the first-line treatment for the menstrual irregularity and hyperandrogenism symptoms among PCOS names covered here, not for the underlying insulin resistance or fertility issue, which needs a different drug class.
No. A meta-analysis conducted for the 2023 guideline update found inositol offers limited clinical benefit relative to metformin for the metabolic features of PCOS, despite similar consumer marketing.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.